Impact of H. pylori eradication on lipid profile in chronic gastritis

  • Iwai N & al.
  • PLoS ONE
  • 1 Jan 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with Helicobacter pylori (H pylori)-associated chronic gastritis, the administration of H pylori eradication therapy was associated with increased high-density lipoprotein (HDL) levels.
  • Low-density lipoprotein (LDL)/HDL ratio significantly decreased at post-eradication vs pre-eradication therapy.

Why this matters

  • Finding suggests that H pylori eradication may prevent arteriosclerosis development by regulating serum lipid concentrations, especially the HDL levels.

Study design

  • Study of 163 patients with H pylori-associated chronic gastritis (mean age, 56.7 years; mean follow-up duration, 514.7 days) who underwent the health screening examination between 2015-2017.
  • Clinical parameters compared before and after H pylori eradication therapy.
  • Funding: None.

Key results

  • Post-eradication vs pre-eradication therapy was associated with significant increase in:
    • weight (60.1±13.9 kg vs 59.6±13.8 kg; P=.001),
    • body mass index (22.6±4.5 kg/m2 vs 22.4±4.5 kg/m2; P=.003),
    • obesity index (2.7±20.5 vs 1.8±20.5; P=.005), and
    • HDL (63.3±15.8 mg/dL vs 61.2±14.7 mg/dL; P<.01>
  • Post-eradication vs pre-eradication therapy significantly decreased WBC (4989.2±1371.1×103/μL vs 5372.1±1359.4×103/μL; P<.001 and platelet count>3/μL vs 24.3 ±5.9×103/μL; P=.001).
  • The LDL/HDL ratio was significantly decreased at post-eradication vs pre-eradication therapy (2.02±0.76 mg/dL vs 2.11±0.75 mg/dL; P<.01>
  • No significant changes were observed in:
    • total cholesterol (206.0±32.5 mg/dL vs 205.1±30.8 mg/dL),
    • LDL (121.2±28.7 mg/dL vs 119.0±27.6 mg/dL),
    • triglycerides (98.1±50.9 mg/dL vs 103.5±58.0 mg/dL), and
    • red blood cells (461.4 ±38.2×106/μL vs 461.9 ±37.5×106/μL; P=.607).

Limitations

  • Retrospective and single-centre study.
  • Small sample size.